Human papillomavirus vaccine recombinant quadrivalent
requires intervention to prevent permanent impairment or damage
First published case report
In a retrospective study, eight female patients aged 15 to 25 years experienced anaphylaxis after receiving the human papillomavirus vaccine recombinant quadrivalent [dosages not stated]. All patients subsequently recovered. A further two girls aged 11 and 12 years developed anaphylactic symptoms which could not be confirmed as anaphylaxis according to the Brighton definition.
A 15-year-old girl received one dose of the human papillomavirus vaccine recombinant quadrivalent [Gardasil]. Less than 5 minutes later, she experienced injection site pain, an urticarial rash on her face, neck and chest, and a generalised prickle sensation. There was a sensation of throat closure, cough, dyspnoea, difficulty talking, a tight, painful chest and wheeziness. She was...
KeywordsSalbutamol Angioedema Chest Tightness Injection Site Pain Urticarial Rash
- 1.Brotherton JML, Gold MS, Kemp AS, McIntyre PB, Burgess MA, Campbell-Lloyd S, New South Wales Health HPV Adverse Events Panel.Anaphylaxis following quadrivalent human papillomavirus vaccination. Canadian Medical Association Journal 179: 525-533, No. 6, 9 Sep 2008 - AustraliaGoogle Scholar